Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Tory P. Sullivan"'
Autor:
Leon H Kircik, Jasmina Jankicevic, Iain Stuart, Deirdre Hooper, Angela Yen Moore, Edward Lain, Martin Zaiac, Tooraj Joseph Raoof, Tory P. Sullivan
Publikováno v:
Journal of the American Academy of Dermatology. 82:832-837
FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV).To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris.A 12-week, multicenter, randomized (1
Autor:
Nicholas Bodor, Janet DuBois, Deepak Chadha, Adam J. Friedman, James Q. Del Rosso, Zakiya Rice, Brandon Kirsch, Adelaide Herbert, Stacy Smith, Tory P. Sullivan, Joe Gorlick, Lawrence Green, Leon H Kircik
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s74
N/A
Publikováno v:
British Journal of Dermatology. 149:1046-1049
Summary Background Hidradenitis suppurativa (HS) is a chronic disease characterized by significant morbidity. Current medical therapies are only minimally effective at treating the disease. Infliximab is a chimeric monoclonal antibody with high affin
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 7:382-386
Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasi
Publikováno v:
Wound Repair and Regeneration. 9:66-76
The medical literature describes numerous in vitro and in vivo wound-healing models. The selection of an animal model depends on a number of factors including availability, cost, ease of handling, investigator familiarity, and anatomical/functional s
Autor:
Pascual Abenoza, Maria Miteva, Paolo Romanelli, Elissa Schwartzfarb, Tory P. Sullivan, Carlos Ricotti, Mehrdad Nadji
Publikováno v:
Journal of Cutaneous Pathology. 36:280-282
Publikováno v:
International Journal of Dermatology. 41:528-530
Autor:
Tory P. Sullivan, William H. Eaglstein
Publikováno v:
Dermatologic clinics. 23(2)
Cyanoacrylates (CAs) were not widely adopted for medical use until recently because of lingering concerns regarding the initial tissue toxicities of the short-chain CAs. The medium-chain CAs, primarily butyl-cyanoacrylate, have been widely used in Eu
Publikováno v:
Journal of cutaneous medicine and surgery. 7(5)
Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn’s disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoria
Publikováno v:
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 29(12)
Objective. To characterize the immune response and the apoptotic pathways that result in regression of imiquimod-treated basal cell carcinomas (BCCs). Methods. The trial was conducted as an open-label, matched controlled, nonrandomized study. Twelve